Skip to main content

Table 2 Univariate and multivariate analyses for sustained virologic response to the combination therapy with peginterferon and ribavirin in patients who underwent response guided therapy according to the AASLD guidelines

From: Significance of a reduction in HCV RNA levels at 4 and 12 weeks in patients infected with HCV genotype 1b for the prediction of the outcome of combination therapy with peginterferon and ribavirin

  Univariate analysis Multivariate analysis* Odds ratio (95% confidence interval)
Age (years) < 0.001 N.S.  
Sex (male/female) 0.005 N.S.  
BMI, median (range) N.S.   
Prior treatment for HCV (no/yes) N.S.   
Pretreatment HCV RNA levels (log10 IU/mL), (≤6.0 vs. 6.0<) 0.015 0.013 2.235 (1.189-4.203)
Platelet count (×103/μL) < 0.001 0.011 1.007 (1.002-1.013)
Hemoglobin (g/dL) 0.002 N.S.  
Neutrophil count (/μL) 0.003 N.S.  
Alanine aminotransferase (IU/L) N.S.   
Total-cholesterol (mg/dL) 0.001 N.S.  
γ-glutamyl transpeptidase (IU/L) 0.014 N.S.  
Fibrosis score (F1 or F2/F3 or F4) < 0.001 N.S.  
Activity score (A1 or A2/A3 or A4) 0.002 N.S.  
Genetic polymorphisms of rs8099917 (TT/GG or TG) < 0.001 < 0.001 5.782 (2.298-14.552)
Amino acid at residue 70 of HCV core (arginine/glutamine or histidine) < 0.001 N.S.  
Amino acid sequence of ISDR (non-wild-type/wild-type) < 0.001 0.038 2.077 (1.041-4.147)
Reduction of HCV RNA [Pre - 4 week] (log10 IU/mL), (≤2.8 vs. 2.8<) < 0.001 < 0.001 3.911 (1.935-7.908)
Reduction of HCV RNA [Pre - 12 week] (log10 IU/mL), (≤4.9 vs. 4.9<) < 0.001 0.013 2.578 (1.220-5.448)
  1. *Multivariate analysis was performed on 314 patients in whom all variables were available.
  2. (N = 516).